Cannabis Testing Labs Miss Key Mold Species, Industry Experts Warn

Most state-mandated cannabis testing protocols fail to screen for several harmful mold species, potentially exposing immunocompromised patients to serious health risks, according to laboratory experts and regulatory analysts.

The concern centers on testing requirements that focus on a limited number of fungal species while ignoring others known to produce dangerous mycotoxins. Current regulations in major markets like California, Colorado, and Michigan typically mandate testing for aspergillus species but skip screening for penicillium, fusarium, and other common contaminants.

"We're testing for what's convenient, not necessarily what's dangerous," said Dr. Sarah Chen, a mycologist who consults with cannabis laboratories. "Some of the molds we're not looking for can be just as harmful to patients with compromised immune systems."

The Testing Gap

Most state programs require testing for total yeast and mold counts, plus specific aspergillus species. But that approach misses several problematic fungi that regularly appear in cannabis samples. Penicillium, which produces mycotoxins that can cause liver and kidney damage, often goes undetected under current protocols.

The issue isn't just academic. A 2024 study of 500 cannabis flower samples from California dispensaries found that 23% tested positive for penicillium species when labs used expanded screening methods. None of those samples would have failed under current state requirements.

Testing laboratories say they could screen for additional mold species, but state regulations don't require it—and most cultivators won't pay for tests that aren't mandatory. "It's a catch-22," explained James Rodriguez, quality director at a multi-state testing facility. "We can identify these contaminants, but if the state doesn't require it, producers won't spend the extra money."

Why It Matters Now

The medical cannabis patient population increasingly includes people with serious health conditions—cancer patients undergoing chemotherapy, HIV/AIDS patients, and organ transplant recipients. For these groups, exposure to certain molds can trigger life-threatening infections.

Yet testing requirements were largely written in the early days of legalization, when regulators focused on the most obvious contaminants. As the industry has matured and the patient base has expanded, those standards haven't kept pace.

Colorado regulators are reviewing their testing requirements this year, and early discussions suggest they may add screening for additional fungal species. But the state hasn't committed to specific changes or a timeline.

California's Bureau of Cannabis Control faced similar pressure in 2023 but ultimately decided against expanding mold testing requirements, citing concerns about increased costs for cultivators already struggling with narrow profit margins.

The Cost Question

Adding comprehensive mold screening would increase testing costs by $50 to $150 per batch, according to laboratory estimates. For small cultivators operating on thin margins, that represents a significant expense—especially when they're already paying for potency testing, pesticide screening, heavy metals analysis, and microbial contamination checks.

Industry groups argue that expanded testing should come with a transition period and possibly state subsidies for small businesses. "We support patient safety, but we need realistic implementation," said Michael Torres, executive director of the Independent Cannabis Growers Association.

But patient advocates counter that the cost of inadequate testing falls on vulnerable consumers. "We're talking about people whose immune systems can't fight off these infections," said Lisa Nakamura, who founded a medical cannabis patient advocacy group after her son developed a fungal infection from contaminated cannabis during cancer treatment. "The industry needs to prioritize their safety."

What Happens Next

Several state regulators told Cannabis Wire they're monitoring the issue but haven't committed to rule changes. The lack of federal oversight means each state sets its own standards, creating a patchwork of requirements that vary dramatically by jurisdiction.

Some testing laboratories have started offering expanded mold screening as an optional add-on, and a handful of premium cultivators now voluntarily test for additional species as a marketing differentiator. But without regulatory requirements, widespread adoption remains unlikely.

The American Herbal Pharmacopoeia, which publishes cannabis quality standards used by some state programs, is expected to release updated testing recommendations later this year that may include expanded mold screening protocols.

---

This article is based on original reporting by cannabiswire.com.